Drug Profile
Polihexanide - SIFI
Alternative Names: AKANTIOR; PHMB; Poliesanide; Polyhexamethylene biguanide hydrochloride - SIFI; Polyhexamethylene biguanide ophthalmic solution - SIFI; polyhexanideLatest Information Update: 12 Jan 2023
Price :
$50
*
At a glance
- Originator SIFI
- Class Antiparasitics; Disinfectants; Polymers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Acanthamoeba infections
Most Recent Events
- 09 Jan 2023 Avanzanite Bioscience and SIFI enters into an agreement to commercialise and distribute Polihexanide in countries within the European economic area and Switzerland
- 09 Jan 2023 SIFI announces intention to submit NDA to the US FDA for Acanthamoeba infections and expects a potential positive opinion by the CHMP for its approval in the EU in 2023
- 13 Oct 2022 Efficacy and adverse events data from a phase III trial in Acanthamoeba infections released by SIFI